Sun Pharmaceutical Industries has reached an agreement to acquire women's health specialist Organon in an all-cash transaction. The deal provides a critical exit for Organon, which has struggled with high debt levels since its 2021 spinoff from Merck.
- All-cash acquisition by Sun Pharma
- Expected purchase price of $14 per share